Sunday, April 27, 2025
8:00 AM – 8:30 AM Registration and Breakfast
8:30 AM –10:00 AM Symposium
The Venetian Convention & Expo Center
201 Sands Avenue
Las Vegas, NV 89169
Meeting Room: Venetian Ballroom J
PROGRAM FEATURES
-
- Interactive, case-based learning environment
- Downloadable Whiteboard Animation
- Create your own Personalized Poster
PRESENTING FACULTY
 |
David R. Staskin, MD Associate Professor of Urology Tufts University School of Medicine St. Elizabeth’s Medical Center Boston, MA |
 |
David O. Sussman, DO, FACOS Clinical Associate Professor Department of Surgery, Division of Urology Section Head, Female Urology and Voiding Rowan University Glassboro, NJ |
PROGRAM OVERVIEW
This program is designed to provide urologists and advanced practice providers in primary care with evidence-based strategies for managing overactive bladder (OAB) in patients receiving treatment for benign prostate hyperplasia (BPH), including an in-depth review of the latest clinical advances in pharmacotherapies, managing treatment-related adverse events, and integrating clinical guideline recommendations into treatment plans. A vivid whiteboard animation depicts the disease state, mechanisms of targeted pharmacotherapies, and associated clinical evidence for learners to explore and gain the knowledge to drive treatment selections more effectively.
LEARNING OBJECTIVES
- Interpret recent clinical evidence on emerging pharmacologic treatments for BPH and OAB
- Apply knowledge of available guidelines to select appropriate pharmacologic treatments for patients with BPH and OAB to optimize patient outcomes in urology practice
- Develop effective management strategies to minimize complications with AEs associated with BPH and OAB treatments to improve patient safety and adherence
TARGET AUDIENCE
This educational activity is intended for urologists and advanced practice providers (APPs) involved in the management of patients with benign prostatic hyperplasia (BPH) and overactive bladder syndrome (OAB).
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]
